Here, Rb protein abundance data played a key role in the robust identification of aggressive breast (ER+ and TNBC) and ovarian tumors that are sensitive to chemotherapy, therefore supporting the use of high-throughput proteomic data in biomarker discovery. This evidence concerns the gene RB1 and ovarian neoplasm.